Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement

Journal of Pharmaceutical and Biomedical Analysis

Volumn 115, Issue , 2015, Pages 359-367

  Szabó, Péter ^a,b   Sebe, István ^b   Stiedl, Bernadett ^a   Kállai Szabó, Barnabás ^b   Zelkó, Romána ^b  

^a GEDEON RICHTER LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Differential scanning calorimetry (DSC); Dissolution enhancement; FTIR; Positron annihilation spectroscopy (PALS); Rotary spun microfiber; X ray diffractometry (XRD)

Indexed keywords

CARVEDILOL; CARBAZOLE DERIVATIVE; EXCIPIENT; PROPANOLAMINE DERIVATIVE; TABLET;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSIBLE TABLET; DISSOLUTION; DRUG SOLUBILITY; IN VITRO STUDY; PARTICLE SIZE; POSITRON ANNIHILATION LIFETIME SPECTROSCOPY; PRIORITY JOURNAL; STRESS; TABLET FORMULATION; TABLET HARDNESS; WATER ABSORPTION; X RAY DIFFRACTION; CHEMICAL MODEL; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; DRUG STABILITY; HARDNESS; INFRARED SPECTROSCOPY; KINETICS; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PH; PHARMACEUTICS; POWDER DIFFRACTION; PROCEDURES; SOLUBILITY; TABLET; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAZOLES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG STABILITY; EXCIPIENTS; HARDNESS; HYDROGEN-ION CONCENTRATION; KINETICS; MODELS, CHEMICAL; POWDER DIFFRACTION; PROPANOLAMINES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84939423105     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.07.042     Document Type: Article

References (44)

1. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
2. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012, 64:4-17.
3. Hann M.M. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2011, 2:349-355.
4. Hann M.M., Keseru G.M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 2012, 11:355-365.
5. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo dioavailability. Pharm. Res. 1995, 12:413-420.
6. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm. Sci. Tech. 2011, 12:62-76.
7. Crowley M.M., Zhang F., Repka M.A., Thumma S., Upadhye S.B., Kumar Battu S., McGinity J.W., Martin C. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev. Ind. Pharm. 2007, 33:909-926.
8. Repka M.A., Battu S.K., Upadhye S.B., Thumma S., Crowley M.M., Zhang F., Martin C., McGinity J.W. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev. Ind. Pharm. 2007, 33:1043-1057.
9. Verreck G., Chun I., Rosenblatt J., Peeters J., Dijck A.V., Mensch J., Noppe M., Brewster M.E. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J. Control. Release 2003, 92:349-360.
10. Balogh A., Farkas B., Faragó K., Farkas A., Wagner I., Van Assche I., Verreck G., Nagy Z.K., Marosi G. Melt-blown and electrospun drug-loaded polymer fiber mats for dissolution enhancement: a comparative study. J. Pharm. Sci. 2015.
11. Huang Z.-M., Zhang Y.Z., Kotaki M., Ramakrishna S. A review on polymer nanofibers by electrospinning and their applications in nanocomposites. Compos. Sci. Technol. 2003, 63:2223-2253.
12. Badrossamay M.R., McIlwee H.A., Goss J.A., Parker K.K. Nanofiber assembly by rotary jet-spinning. Nano Lett. 2010, 10:2257-2261.
13. Szabó P., Kallai-Szabó B., Kallai-Szabó N., Sebe I., Zelkó R. Preparation of hydroxypropyl cellulose microfibers by high-speed rotary spinning and prediction of the fiber-forming properties of hydroxypropyl cellulose gels by texture analysis. Cellulose 2014, 21:4419-4427.
14. Kim T.G., Lee D.S., Park T.G. Controlled protein release from electrospun biodegradable fiber mesh composed of poly(ε-caprolactone) and poly(ethylene oxide). Int. J. Pharm. 2007, 338:276-283.
15. Zeng J., Yang L., Liang Q., Zhang X., Guan H., Xu X., Chen X., Jing X. Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation. J. Control. Release 2005, 105:43-51.
16. Seif S., Franzen L., Windbergs M. Overcoming drug crystallization in electrospun fibers - elucidating key parameters and developing strategies for drug delivery. Int. J. Pharm. 2015, 478:390-397.
17. Zelko R., Orban A., Suvegh K. Tracking of the physical ageing of amorphous pharmaceutical polymeric excipients by positron annihilation spectroscopy. J. Pharm. Biomed. Anal. 2006, 40:249-254.
18. Süvegh K., Zelkó R. Physical aging of poly(vinylpyrrolidone) under different humidity conditions. Macromolecules 2002, 35:795-800.
19. Kiss D., Süvegh K., Marek T., Dévényi L., Novák C., Zelkó R. Tracking the physical aging of poly(ethylene oxide): a technical note. AAPS Pharm. Sci. Tech. 2006, 7:E95-E98.
20. Kaushal A.M., Chakraborti A.K., Bansal A.K. FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol. Pharm. 2008, 5:937-945.
21. Frishman W.H. Carvedilol. N. Engl. J. Med. 1998, 339:1759-1765.
22. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 1994, 26:335-346.
23. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996, 334:1349-1355.
24. Ruffolo R., Feuerstein G. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 1997, 11:247-256.
25. Zhao Q., Wang T., Wang J., Zheng L., Jiang T., Cheng G., Wang S. Template-directed hydrothermal synthesis of hydroxyapatite as a drug delivery system for the poorly water-soluble drug carvedilol. Appl. Surf. Sci. 2011, 257:10126-10133.
26. Möllendorff E.V., Reiff K., Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. E. J. Clin. Pharmacol. 1987, 33:511-513.
27. Planinšek O., Kovačič B., Vrečer F. Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. Int. J. Pharm. 2011, 406:41-48.
28. Potluri R.H., Bandari S., Jukanti R., Veerareddy P.R. Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13. Arch. Pharm. Res. 2011, 34:51-57.
29. Singh B., Khurana L., Bandyopadhyay S., Kapil R., Katare O.O.P. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv. 2011, 18:599-612.
30. Sanjula B., Shah F.M., Javed A., Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Targeting 2009, 17:249-256.
31. Venishetty V.K., Chede R., Komuravelli R., Adepu L., Sistla R., Diwan P.V. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf. B: Biointerfaces 2012, 95:1-9.
32. Gellad W.F., Grenard J.L., Marcum Z.A. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am. J. Geriatric Pharm. 2011, 9:11-23.
33. Breitkreutz J., Tuleu C. Pediatric and geriatric pharmaceutics and formulation. Modern Pharm. 2009, 221-258.
34. Bandari S., Mittapalli R.K., Gannu R., Rao Y.M. Orodispersible tablets: an overview. Asian J. Pharm. 2008, 2.
35. Szabó P., Kallai-Szabó B., Sebe I., Zelkó R. Preformulation study of fiber formation and formulation of drug-loaded microfiber based orodispersible tablets for in vitro dissolution enhancement. Int. J. Pharm. 2014, 477:643-649.
36. Süvegh K., Vértes A., Hyodo T. Positronium as a sensitive detector of changes in molecular structure. Adv. Mol. Struct. Res. 1999, 5:313-358.
37. Deng Q., Jean Y.C. Free-volume distributions of an epoxy polymer probed by positron annihilation: pressure dependence. Macromolecules 1993, 26:30-34.
38. Kirkegaard P., Eldrup M., Mogensen O.E., Pedersen N.J. Program system for analysing positron lifetime spectra and angular correlation curves. Comput. Phys. Commun. 1981, 23:307-335.
39. Moore J.W., Flanner H.H. Mathematical comparison of dissolution profiles. Pharm. Technol. 1996, 20:64-74.
40. Sebe I., Bodai Z., Eke Z., Kallai-Szabo B., Szabo P., Zelkó R. Comparison of directly compressed vitamin B 12 tablets prepared from micronized rotary-spun microfibers and cast films. Drug Dev. Ind. Pharm. 2014, 1-5.
41. Sebe I., Szabó B., Nagy Z.K., Szabó D., Zsidai L., Kocsis B., Zelkó R. Polymer structure and antimicrobial activity of polyvinylpyrrolidone-based iodine nanofibers prepared with high-speed rotary spinning technique. Int. J. Pharm. 2013, 458:99-103.
42. Repka M.A., Gutta K., Prodduturi S., Munjal M., Stodghill S.P. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur. J. Pharm. Biopharm. 2005, 59:189-196.
43. Mohammed N.N., Majumdar S., Singh A., Deng W., Murthy N.S., Pinto E., Tewari D., Durig T., Repka M.A., Klucel E.F. ELF polymers for immediate-release oral dosage forms prepared by melt extrusion technology. AAPS Pharm. Sci. Tech. 2012, 13:1158-1169.
44. Ghanbarzadeh B., Almasi H., Entezami A.A. Improving the barrier and mechanical properties of corn starch-based edible films: effect of citric acid and carboxymethyl cellulose. Ind. Crops Prod. 2011, 33:229-235.